We have carried out a high-resolution whole genome DNA profiling analysis on 100 bone marrow samples from a consecutive series of de novo acute myeloid leukemia (AML) cases. After discarding copy number changes that are known to be genetic polymorphisms, we found that genomic aberrations (GA) in the form of gains or losses of genetic material were present in 74% of the samples, with a median of 2 GA per case (range 0-35). In addition to the cytogenetically detected aberration, GA were present in cases from all cytogenetic prognostic groups: 79% in the favorable group, 60% in the intermediate group (including 59% of cases with normal karyotype) and 83% in the adverse group. Five aberrant deleted regions were recurrently associated with cases with a highly aberrant genome (e.g., a 1.5 Mb deletion at 17q11.2 and a 750 kb deletion at 5q31.1). Different degrees of genomic instability showed a statistically significant impact on survival curves, even within the normal karyotype cases. This association was independent of other clinical and genetic parameters. Our study provides, for the first time, a detailed picture of the nature and frequency of DNA copy number aberrations in de novo AML.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease that accounts for about 30% of all adult leukemias. 1 Despite improvements in clinical management, death rates are still over 60% for patients younger than 65. Benefits from current and emerging therapies will largely rely on appropriate stratification of AML patients at diagnosis. The World Health Organization (WHO) classification of AML uses patients' age, white blood cell count (WBC), morphology, immunohistochemistry, and cytogenetics, which are determinant clinical variables, to categorize the disease properly. 2 Cytogenetic studies are used to stratify patients into three groups of prognosis according to overall survival (OS): favorable, intermediate and adverse. 3, 4 The favorable group is composed of AMLs associated with t(8;21), inv (16) or t (15;17) . The adverse group includes complex karyotypes, t(6;9) and del(5q), among others. 5 The intermediate prognosis group is heterogeneous and includes cases with normal karyotype (NK) (40-50% of AML) 6 and trisomy 8, among others. 7 Lately, several studies have focused on the importance of searching for specific receptor tyrosine kinase mutations, such as tandem duplications in FLT3 or mutations in NPM1, [8] [9] [10] [11] [12] as markers of prognosis in AML. Genomic technologies, not yet implemented in routine clinical practice, such as expression microarrays, are useful tools to identify molecular subgroups with distinct gene expression signatures. 13, 14 However, optimal RNA samples are difficult to obtain and expression signatures are not always reproducible. In fact, since it is known that AML is commonly characterized by chromosome aberrations that result in deletions or gains of large genome regions, other approaches that are DNA-based are, in principle, more suitable to study the genetic features of this disease. In this regard, although SNP microarrays have been recently used to determine regions of partial uniparental disomy that are not visible using other chromosomal aberration studies, 15 array-based comparative genomic hybridization (arrayCGH) stands up as a more optimal approach to find lost and gained regions among the cancer genome. [16] [17] [18] [19] Recently, oligonucleotide-based arrayCGH techniques have greatly increased the number of clones represented in an array, fostering expectations of determining smaller regions of aberration in cancer. 20 With the intention of providing a more complete genetic and genomic characterization of this disease, we have carried out the first high-resolution (44 000 probes) arrayCGH study in a series of 100 consecutively ascertained samples of de novo AML.
Materials and methods

Patient selection, cytogenetics and clinical data
Bone marrow samples were selected from a series of 140 consecutive de novo AML patients recruited for diagnosis. Exclusion criteria were AML cases positive for PML/RARA or t(15;17), a previous history of myelodysplasia or cytotoxic drugs or radiation, low quality and/or amount of genomic DNA from the sample and/or absence of relevant clinical data. Hematological, WHO classification, conventional cytogenetics, flourescence in situ hybridization (FISH), FLT3-ITD molecular studies, (only for NK cases 21 ) and clinical follow-up were available in 100 samples. Clinical data and leukemia cell characterization are summarized in Table 1 . All samples were stored after diagnosis and obtaining informed consent. All patients were uniformly treated according to the PETHEMA LAM99 protocol. 22 Samples were classified into three subgroups according to the CALGB cytogenetics cumulative incidence of relapse classification system: 4 14 belonged to the favorable prognosis group, 74 to the intermediate prognosis group and 12 to the adverse prognosis group.
ArrayCGH and management of genetic polymorphisms
Human Genome CGH 44k microarrays (Agilent Technologies, Palo Alto, CA, USA), versions A and B, were used. Hybridizations were performed according to the manufacturer's protocols as described previously. 20 DNA from 15 healthy women was extracted to create a donor DNA pool to be used as reference and to minimize the effect of individual genetic polymorphisms on the estimation of the DNA copy number changes present in the patients' samples. Microarray data were extracted and visualized using Feature Extraction Software v8.1 and CGH Analytics v3.2.25, (Agilent Technologies). Categorized copy number values (0, 1 or À1 indicating no change, gain or loss, respectively) were obtained using Insilico array CGH software. 23 We defined a genomic aberration (GA) as a group of at least two consecutive probes showing the same non-zero categorized copy number value. Single-probe aberrations did not score as genomic aberrations. The existence of a large number of genetic polymorphisms that originate as duplication and deletion of genomic regions of varying sizes has been previously described and annotated. 24 To avoid overestimation of the number of genomic aberrations, due to such polymorphisms being detected by the arrayCGH platform, we eliminated all DNA copy changes observed in our samples that showed at least 80% of their sequence overlapping with the known polymorphisms included in the latest version (20 December 2006) of the Database of Genomic Variants. 24 Definition and validation of smallest overlapping regions of imbalance Aberrant regions were used to obtain the smallest overlapping regions of imbalance (SORI). Each SORI represents a recurrent region of imbalance whose limits were defined by the minimum number of consecutive clones with identical aberrations in at least two cases. 25 SORI limits were determined as the clones placed at the boundaries of the gained or lost region of the case showing the smallest unbalanced region (a representative example is provided in Figure 1 ). Multiplex ligation-dependent probe amplification and FISH assays were performed as described previously 26, 27 to validate copy number changes obtained in the arrays (data not shown).
Bioinformatics and statistical analysis
SORIs were subjected to supervised clustering analysis using GEPAS Suite software. 23 Associations between genomic instability and other clinical parameters were assessed using Fisher's exact test for qualitative variables and the KruskalWallis test for quantitative factors. Kaplan-Meyer curves were drawn and the log-rank test and multivariate Cox regression applied using SPSS v13.0 (Lead Technologies, Inc., Charlotte, NC, USA) to test for differences in overall survival between groups. Factors with Po0.1 in univariate analysis and wellknown prognostic markers (FLT3 and WBC) were included in the multivariate regression. Nine AML cases for whom clinical evolution data were not recovered were excluded from the analysis.
Results
Frequency of genomic instability
Using oligonucleotide-based arrayCGH, we initially identified genomic imbalances in more than 90% of the cases. After the elimination of known polymorphisms, 24 a total of 74% of the cases remained as displaying an aberrant genome, with a median number of two altered regions per case (range 0-35). A complete description of all identified copy number variants is provided in Supplementary Tables 1 and 2 . DNA aberrations Cytogenetic classification based upon the CALGB study.
were observed in all cytogenetic groups ( Array CGH in de novo AML J Suela et al series into two major groups according to the median number of GA per case (see scheme in Supplementary Figure 1) . One group was characterized by a low number of changes (0-1) and included 46 cases. The remaining cases displayed a higher number of GA with a wide range of values . In an attempt to minimize the effect of this large variability, the second group was again segregated into two subgroups according to the median number of changes: 3 30 cases with 2 or 3 GA per case, and a last group of 24 cases with four or more GA. The distribution of the cytogenetic prognosis groups across these genomic aberration groups is also shown in Table 2 .
Description of smallest overlapping regions of imbalance
We identified 92 SORI that included 62 losses and 30 gains (Supplementary Table 3 ). The frequency of SORI ranged from 2 to 15%. Six aberrant regions were observed in more than 5% of the series: five losses of less than 2 Mb involving chromosomes 5, 7, 17 and 20; and one gain that corresponded to trisomy 8 and represented the most recurrent change (15% of cases). The median size of the SORI was 243 kb for gains (ranging from 3 kb to 147 Mb) and 364 kb for losses (ranging from 739 bp to 32.5 Mb). We evaluated whether any SORI were associated with the previously defined GA groups, by supervised clustering. We identified five regions of interest (s-SORI) which clearly differentiated the cases with GA X4 (Po0.05) ( Table 3 ). All the s-SORI corresponded to deletions in chromosomes 5, 16 (included two s-SORI), 17 and 18 and all were validated by FISH (Figure 1 ). Deletion sizes ranged from a few kb (in 16q24) to 6 Mb (in 18p11.2). In spite of the lack of recurrence for specific changes, among 24 cases with four or more GA (which also included five cases from the favorable group), nine (38%) showed deletion of at least one of these five s-SORI.
Association between genomic profiles and survival
We tested associations with OS in our series for several potentially prognostic variables and clinical parameters ( Table 4) . As expected, cytogenetic prognosis group and age at diagnosis were statistically and significantly associated with OS (Po0.05) in the univariate analyses. The proposed genomic instability classification was also associated with survival, regardless of whether the two or three group classification was considered (P ¼ 0.007 or P ¼ 0.002, respectively). Cases with a more aberrant genome had a worse prognosis (Figure 2a) . Additionally, we assessed the effect of deleted SORI that characterized the highly unstable group of AML (s-SORI, Table 3 ) Table 2 Median number of GA per case according to cytogenetic and instability classification groups Table 5 ) and found that only genomic instability was a statistically significant prognostic factor (P ¼ 0.045) (Figure 2b ).
Discussion
Conventional karyotyping has been used until now as the main tool for assigning a patient to a predictive prognosis group at diagnosis, but it has been demonstrated that karyotyping alone is insufficient to predict outcome. 28 Experiments using expression arrays have proved that, within the favorable prognosis group, there are statistical and biological differences in expression profiling and survival. 29, 30 Many of these differences may have originated through mutational or epigenetic alterations that contributed to the variability of the disease. 31, 32 Other molecular cytogenetic techniques have also unveiled new chromosomal rearrangements which were not visible by karyotyping. [16] [17] [18] [19] 33, 34 We have used a genomic array with more than 40 000 probes that offers a median resolution of 75 kb and whose composition is biased towards known genes. We have analyzed 100 samples from a series of consecutively ascertained cases, an optimal experimental design that provides a comprehensive and complete picture of the genomic features of the disease. Previous studies dealing with the genomic characterization of AML have been reported, but have failed either to cover all the cytogenetic subtypes 18, 19, 35 or to provide a complete high resolution description of gained and deleted regions that occurred in their series because they were based on SNP-array technology and focused exclusively on the loss of heterozygosity analysis. Array CGH in de novo AML J Suela et al
15,36
As a consequence of our design, we have demonstrated that AML is a genomically heterogeneous disease that is characterized by a high incidence of small and non-recurrent DNA copy number aberrations. In general, cytogenetic and genomic classifications showed a high degree of correlation (Supplementary Table 6 ), probably due to the fact that both are based on similar causal events (genetic errors). As expected, most of the described recurrent GA were carried by cases with a complex karyotype. However, the identification of GA in a substantial proportion of cases that were classified in the favorable and intermediate cytogenetic prognostic groups is a novel finding. Additional GA were detected in 60% of cases with normal karyotype, in contrast with previous studies where this percentage was less than 20%. 15, 36 An explanation for this difference may be the higher resolution of our arrayCGH platform, as well as its greater efficacy in detecting genomic gains compared to the previous reports using SNP-based platforms. Recently, a new manuscript working with array-CGH detected aberrations in 15% of NK-AML, showing aberrations from 0.4 to 4.1 Mb. 35 The conclusions of all these studies suggest that normal karyotype AML may have GA but with no consistence or recurrence in the affected regions. More surprisingly, 10 out of the 14 cases with favorable prognosis had unstable genomes. Among them, five cases had highly unstable genomes, including two cases with inv(16) that showed deletions in the 5q31.1 and 17q1.2 regions (two of the s-SORI). Although it has been demonstrated that additional cytogenetic abnormalities have no impact on the outcome of patients with favorable cytogenetics, 4, 5 our results suggest that this may not be the case when arrayCGH aberrations (otherwise unnoticed by conventional cytogenetics) are taken into account.
We have also demonstrated, with a resolution of 75 kb, that there is a low recurrence of relevant or specific GA. This is in concordance with larger studies where the low recurrence of copy number aberrations in AML has been demonstrated at the cytogenetic level. 4 Only trisomy 8, reported as the most recurrent change in AML (frequency 45%), 3, 33, 37, 38 was also observed in our series in more than 10% of cases. On the basis of the heterogeneity of genomic changes that we have observed in our series, we suggest that, rather than searching for specific or unique recurrent aberrations, AML should be studied in terms of patterns of genomic instability. Genomic instability has been proposed to be a measure of clinical outcome prediction in other cancer studies. 39, 40 Recent studies have shown that polymorphisms in some DNA repair genes may be used as markers of poor prognosis in AML, 41 meaning that DNA repair genes are crucial in avoiding instability. Our genomic stability classification seemed to be efficient in segregating groups with different survival. Furthermore, this association was independent of other known clinical and genetic parameters as age, WBC or cytogenetics classification.
We considered the effect of FLT3-ITD mutational status by carrying out a separate analysis in the subset of NK cases (Supplementary Table 5 ). Although the detection of FLT3-ITD showed no association with OS (probably due to the sample size), NK cases with GA had a statistically significant worse prognosis (8% 5-year OS) than NK cases with less than 2 GA (46%).
The definition of minimal regions is a common part of the analysis in array-CGH studies. In the absence of available software to perform this type of analysis, SORIs were defined by compiling all GA from each case along the entire genome (as has been previously reported. 25 A schematic example of the 17q11.2 region is shown in Figure 1 . The two identified s-SORI, 5q31.1 and 17q11.2 regions are of particular interest within the context of AML. 5q has been widely studied in myeloid leukemias, being an important marker of karyotype complexity. 34, 42 Genes included in the deleted 5q31.1 region are PPP2CA, SKP1A, UBE2B and CDKL3. PPP2CA, the isoform a of the catalytic subunit of the protein phosphatase 2, has been shown to play a crucial role in DNA repair: loss of function of this phosphatase leads to inefficient DNA repair and to further hypersensibility to DNA damage. 43 The minimal region at 17q11.2 (approximately 1.5 Mb) is homogeneously deleted (four cases showed deletions of less than 4 Mb including this region and only one case had a deletion above 15 Mb). It includes several genes, including neurofibromatosis-1 (NF1). NF1 is a large tumor suppressor gene (over 350 kb), responsible for the autosomal-dominant disorder know as NF1 syndrome (or Von Recklinghausens's neurofibromatosis). These patients have an increased risk of various tumors, including myeloid hematological disorders. 44 Recently, it has been described that affected children with NF1 may develop myeloid malignancies after losing their wild-type NF1 allele due to interstitial uniparental disomy. 45 To date, mutations in NF1 have not been identified in adult patients with any myeloid disorders 46 but, it has been recently demonstrated that hemizygotic NF1 mice are more sensitized to carcinogenic stimuli, which result in hematological disorders independent of mutation of Trp53. 47 The NF1 gene has also been shown to be downregulated by the AML1-ETO fusion gene, which represses NF1 gene expression, resulting in RAS overexpression. 48 Recently, NF1 cryptic deletion was described in a case of secondary AML 49 and in a study of complex karyotype AML. 19 These findings show that, in concordance with our data, NF1 may play an important role in poor prognosis leukemia. Unfortunately, detection of mutations in NF1 or PPP2CA requires a large amount of fresh material (RNA or intact cells), which was not available for our samples.
In conclusion, our study provides evidence that genomic instability is a common feature in AML. This instability results in a median of 2 GA per case and it affects all cytogenetic groups with variable incidence (always more than 60%). However, recurrence of specific changes was observed only in cases with highly aberrant genomes. DNA profiling produces genomic patterns that could be used to segregate patients into groups with a potential role in predicting survival. Further studies may help to confirm our findings and should be followed by functional analyses to explain the implications of our regions of interest in leukemia.
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